Linked Life Data

15028245

Source:http://linkedlifedata.com/resource/pubmed/id/15028245

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15028245rdf:typepubmed:Citationlld:pubmed
pubmed-article:15028245lifeskim:mentionsumls-concept:C0031809lld:lifeskim
pubmed-article:15028245lifeskim:mentionsumls-concept:C0024399lld:lifeskim
pubmed-article:15028245lifeskim:mentionsumls-concept:C0031268lld:lifeskim
pubmed-article:15028245lifeskim:mentionsumls-concept:C0006104lld:lifeskim
pubmed-article:15028245lifeskim:mentionsumls-concept:C0040615lld:lifeskim
pubmed-article:15028245lifeskim:mentionsumls-concept:C0084528lld:lifeskim
pubmed-article:15028245lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:15028245lifeskim:mentionsumls-concept:C1441547lld:lifeskim
pubmed-article:15028245lifeskim:mentionsumls-concept:C0243144lld:lifeskim
pubmed-article:15028245lifeskim:mentionsumls-concept:C0243076lld:lifeskim
pubmed-article:15028245pubmed:issue3lld:pubmed
pubmed-article:15028245pubmed:dateCreated2004-3-18lld:pubmed
pubmed-article:15028245pubmed:abstractTextCentral alpha(1)-adrenergic receptors are potential targets for recently developed antipsychotic drugs. Two new 11C labeled potent and selective alpha(1)-adrenoceptor antagonists, 1- [2- [4-[1-(4-fluorophenyl)-5-(2-[(11)C]methyl-tetrazol-5-yl)-1H-indol-3-yl]-1-piperidinyl]ethyl]-imidazolidin-2-one ([(11)C]2) and 1- [2- [4-[1-(4-fluorophenyl)-5-(1-[(11)C]methyl-(1,2,3-triazol-4-yl)-1H-indol-3-yl]-1-piperidinyl]ethyl]-imidazolidin-2-one ([(11)C]3) were prepared and evaluated for imaging of central alpha(1)-adrenergic receptors in the cynomolgus monkey brain. For both compounds, the total brain radioactivity was only about 0.6% of the radioactivity injected i.v. There was no evident binding in regions known to contain alpha(1)-adrenoceptors. This observation suggests that the affinity of the radioligands in primates in vivo is not sufficient to provide a signal for specific binding that can be differentiated from the background. In addition, active efflux by P-glycoprotein may be responsible for the low total brain-uptake of the two radioligands. Both compounds showed a highly polarised and verapamile sensitive transport across monolayers of Caco-2 cells. The total brain-uptake of [(3)H]2 was 6 times higher in mdr1a(-/-) knock-out mice lacking the gene encoding P-glycoprotein compared to wild type mice. Pretreatment of one monkey with Cyclosporin A (15 mg/kg) resulted in 40% higher brain uptake for [(11)C]3 when compared with baseline. These observations support the view that efflux by P-glycoprotein can be of quantitative importance for the total brain-uptake of some PET radioligands.lld:pubmed
pubmed-article:15028245pubmed:languageenglld:pubmed
pubmed-article:15028245pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15028245pubmed:citationSubsetIMlld:pubmed
pubmed-article:15028245pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15028245pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15028245pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15028245pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15028245pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15028245pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15028245pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15028245pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15028245pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15028245pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15028245pubmed:statusMEDLINElld:pubmed
pubmed-article:15028245pubmed:monthAprlld:pubmed
pubmed-article:15028245pubmed:issn0969-8051lld:pubmed
pubmed-article:15028245pubmed:authorpubmed-author:HalldinChrist...lld:pubmed
pubmed-article:15028245pubmed:authorpubmed-author:FardeLarsLlld:pubmed
pubmed-article:15028245pubmed:authorpubmed-author:AndersenKimKlld:pubmed
pubmed-article:15028245pubmed:authorpubmed-author:BalleThomasTlld:pubmed
pubmed-article:15028245pubmed:authorpubmed-author:PerregaardJen...lld:pubmed
pubmed-article:15028245pubmed:authorpubmed-author:AndersenLinus...lld:pubmed
pubmed-article:15028245pubmed:authorpubmed-author:Hjorth...lld:pubmed
pubmed-article:15028245pubmed:authorpubmed-author:BadoloLassina...lld:pubmed
pubmed-article:15028245pubmed:authorpubmed-author:Gjervig...lld:pubmed
pubmed-article:15028245pubmed:authorpubmed-author:ChouYuan-WhaY...lld:pubmed
pubmed-article:15028245pubmed:issnTypePrintlld:pubmed
pubmed-article:15028245pubmed:volume31lld:pubmed
pubmed-article:15028245pubmed:ownerNLMlld:pubmed
pubmed-article:15028245pubmed:authorsCompleteYlld:pubmed
pubmed-article:15028245pubmed:pagination327-36lld:pubmed
pubmed-article:15028245pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:meshHeadingpubmed-meshheading:15028245...lld:pubmed
pubmed-article:15028245pubmed:year2004lld:pubmed
pubmed-article:15028245pubmed:articleTitleNew alpha(1)-adrenoceptor antagonists derived from the antipsychotic sertindole - carbon-11 labelling and pet examination of brain uptake in the cynomolgus monkey.lld:pubmed
pubmed-article:15028245pubmed:affiliationKarolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital, S-171 76 Stockholm, Sweden. tb@dfuni.dklld:pubmed
pubmed-article:15028245pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15028245pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:15028245pubmed:publicationTypeEvaluation Studieslld:pubmed